# Datacentrex, Inc.: financial statements, quarterly

DTCX · Nasdaq · CIK 1853825 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dtcx.md) · [Financials](/companies/dtcx/financials.md) · [Filings](/companies/dtcx/filings.md) · [Insiders](/companies/dtcx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dtcx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001493152-24-031275.md) | [0.0](/filings/0001493152-24-045795.md) | [(0.0) d](/filings/0001493152-25-009872.md) | [0.0](/filings/0001641172-25-011020.md) | [0.0](/filings/0001493152-25-011978.md) | [0.0](/filings/0001493152-25-023656.md) | [0.0 d](/filings/0001493152-25-009872.md) | [0.2](/filings/0001493152-26-023091.md) | [1.9](/filings/0001493152-26-037377.md) | [0.0](/filings/0001493152-25-023656.md) | [2.2](/filings/0001493152-26-023091.md) | [1.9](/filings/0001493152-26-037377.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001493152-26-023091.md) | [1.0](/filings/0001493152-26-037377.md) | not reported | [1.7](/filings/0001493152-26-023091.md) | [1.7](/filings/0001493152-26-037377.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001493152-26-023091.md) | [0.9](/filings/0001493152-26-037377.md) | not reported | [0.5](/filings/0001493152-26-023091.md) | [0.2](/filings/0001493152-26-037377.md) |
| Research and development | $m | [0.2](/filings/0001493152-24-031275.md) | [0.2](/filings/0001493152-24-045795.md) | [0.0 d](/filings/0001493152-25-009872.md) | [0.0](/filings/0001641172-25-011020.md) | [0.0](/filings/0001493152-25-011978.md) | [0.0](/filings/0001493152-25-023656.md) | [0.1 d](/filings/0001493152-25-009872.md) | [0.1](/filings/0001641172-25-011020.md) | [0.1](/filings/0001493152-25-011978.md) | [(0.0)](/filings/0001493152-25-023656.md) | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-26-023091.md) | [0.0](/filings/0001493152-26-037377.md) | not reported | [0.0](/filings/0001493152-26-023091.md) | [0.0](/filings/0001493152-26-037377.md) |
| Operating income | $m | [(0.7)](/filings/0001493152-24-031275.md) | [(0.7)](/filings/0001493152-24-045795.md) | [(0.4) d](/filings/0001493152-25-009872.md) | [(0.3)](/filings/0001641172-25-011020.md) | [(0.5)](/filings/0001493152-25-011978.md) | [(0.4)](/filings/0001493152-25-023656.md) | [(2.6) d](/filings/0001493152-25-009872.md) | [(0.3)](/filings/0001493152-26-023091.md) | [(1.4)](/filings/0001493152-26-037377.md) | [(10.6)](/filings/0001493152-25-023656.md) | [(5.0)](/filings/0001493152-26-023091.md) | [(4.8)](/filings/0001493152-26-037377.md) |
| Interest expense | $m | [0.0](/filings/0001493152-23-029584.md) | [0.0](/filings/0001493152-23-040633.md) | [0.0 d](/filings/0001493152-24-010691.md) | not reported | [(0.0)](/filings/0001493152-24-031275.md) | [(0.0)](/filings/0001493152-24-045795.md) | [0.1 d](/filings/0001493152-25-009872.md) | not reported | not reported | [0.0](/filings/0001493152-25-023656.md) | not reported | not reported |
| Net income | $m | [(0.9)](/filings/0001493152-24-031275.md) | [(1.1)](/filings/0001493152-24-045795.md) | [(0.4) d](/filings/0001493152-25-009872.md) | [(0.3)](/filings/0001641172-25-011020.md) | [(0.5)](/filings/0001493152-25-011978.md) | [(0.4)](/filings/0001493152-25-023656.md) | [(2.7) d](/filings/0001493152-25-009872.md) | [(0.3)](/filings/0001493152-26-037377.md) | [(1.5)](/filings/0001493152-26-037377.md) | [(10.5)](/filings/0001493152-25-023656.md) | [(6.2)](/filings/0001493152-26-037377.md) | [(5.5)](/filings/0001493152-26-037377.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001493152-24-031275.md) | [(0.15)](/filings/0001493152-24-045795.md) | not reported | [(0.04)](/filings/0001641172-25-011020.md) | [(0.07)](/filings/0001493152-25-011978.md) | [(0.06)](/filings/0001493152-25-023656.md) | not reported | [(0.22)](/filings/0001641172-25-011020.md) | [(0.12)](/filings/0001493152-25-011978.md) | [(0.77)](/filings/0001493152-25-023656.md) | [(0.20)](/filings/0001493152-26-023091.md) | [(0.14)](/filings/0001493152-26-037377.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001493152-24-031275.md) | [(0.15)](/filings/0001493152-24-045795.md) | not reported | [(0.04)](/filings/0001641172-25-011020.md) | [(0.07)](/filings/0001493152-25-011978.md) | [(0.06)](/filings/0001493152-25-023656.md) | not reported | [(0.22)](/filings/0001641172-25-011020.md) | [(0.12)](/filings/0001493152-25-011978.md) | [(0.77)](/filings/0001493152-25-023656.md) | [(0.20)](/filings/0001493152-26-023091.md) | [(0.14)](/filings/0001493152-26-037377.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.1](/filings/0001493152-23-040633.md) | [0.3](/filings/0001493152-25-009872.md) | [0.2](/filings/0001493152-24-019330.md) | [0.4](/filings/0001493152-24-031275.md) | [0.1](/filings/0001493152-24-045795.md) | [4.7](/filings/0001493152-25-023656.md) | [1.0](/filings/0001641172-25-011020.md) | [0.1](/filings/0001493152-25-011978.md) | [44.1](/filings/0001493152-25-023656.md) | [38.9](/filings/0001493152-26-037377.md) | [42.5](/filings/0001493152-26-023091.md) | [51.9](/filings/0001493152-26-037377.md) |
| Current assets | $m | [0.2](/filings/0001493152-23-040633.md) | [0.3](/filings/0001493152-25-009872.md) | [0.4](/filings/0001493152-24-019330.md) | [0.5](/filings/0001493152-24-031275.md) | [0.2](/filings/0001493152-24-045795.md) | [4.8](/filings/0001493152-25-023656.md) | [1.3](/filings/0001641172-25-011020.md) | [0.2](/filings/0001493152-25-011978.md) | [44.8](/filings/0001493152-25-023656.md) | [43.8](/filings/0001493152-26-037377.md) | [59.7](/filings/0001493152-26-023091.md) | [58.5](/filings/0001493152-26-037377.md) |
| Total assets | $m | [0.3](/filings/0001493152-23-040633.md) | [0.4](/filings/0001493152-25-009872.md) | [0.5](/filings/0001493152-24-019330.md) | [0.7](/filings/0001493152-24-031275.md) | [0.4](/filings/0001493152-24-045795.md) | [5.1](/filings/0001493152-25-023656.md) | [3.2](/filings/0001641172-25-011020.md) | [2.6](/filings/0001493152-25-011978.md) | [51.7](/filings/0001493152-25-023656.md) | [66.8](/filings/0001493152-26-037377.md) | [79.4](/filings/0001493152-26-023091.md) | [74.9](/filings/0001493152-26-037377.md) |
| Current liabilities | $m | [0.1](/filings/0001493152-23-040633.md) | [0.1](/filings/0001493152-25-009872.md) | [0.1](/filings/0001493152-24-019330.md) | [0.1](/filings/0001493152-24-031275.md) | [0.2](/filings/0001493152-24-045795.md) | [0.3](/filings/0001493152-25-023656.md) | [0.4](/filings/0001641172-25-011020.md) | [0.8](/filings/0001493152-25-011978.md) | [0.9](/filings/0001493152-25-023656.md) | [0.6](/filings/0001493152-26-037377.md) | [0.3](/filings/0001493152-26-023091.md) | [0.3](/filings/0001493152-26-037377.md) |
| Total liabilities | $m | [0.1](/filings/0001493152-23-040633.md) | [0.1](/filings/0001493152-25-009872.md) | [0.1](/filings/0001493152-24-019330.md) | [0.1](/filings/0001493152-24-031275.md) | [0.2](/filings/0001493152-24-045795.md) | [0.3](/filings/0001493152-25-023656.md) | [0.4](/filings/0001641172-25-011020.md) | [0.8](/filings/0001493152-25-011978.md) | [0.9](/filings/0001493152-25-023656.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [0.1](/filings/0001493152-24-045795.md) | [0.3](/filings/0001493152-25-023656.md) | [0.5](/filings/0001493152-25-011978.md) | [0.6](/filings/0001493152-25-023656.md) | [0.2](/filings/0001493152-25-023656.md) | [4.8](/filings/0001493152-25-023656.md) | [17.6](/filings/0001493152-26-037377.md) | [26.5](/filings/0001493152-26-037377.md) | [50.8](/filings/0001493152-25-023656.md) | [66.2](/filings/0001493152-26-037377.md) | [79.2](/filings/0001493152-26-037377.md) | [74.5](/filings/0001493152-26-037377.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.7) d](/filings/0001493152-24-031275.md) | [(0.6) d](/filings/0001493152-24-045795.md) | [(0.4) d](/filings/0001493152-25-009872.md) | [(0.3)](/filings/0001641172-25-011020.md) | [(0.4) d](/filings/0001493152-25-011978.md) | [(0.4) d](/filings/0001493152-25-023656.md) | [(2.4) d](/filings/0001493152-25-009872.md) | [(1.3)](/filings/0001493152-26-023091.md) | [(1.1) d](/filings/0001493152-26-037377.md) | [(2.6) d](/filings/0001493152-25-023656.md) | [(3.2)](/filings/0001493152-26-023091.md) | [(1.8) d](/filings/0001493152-26-037377.md) |
| Capital expenditure | $m | not reported | [0.0 d](/filings/0001493152-24-045795.md) | [0.0 d](/filings/0001493152-25-009872.md) | not reported | not reported | not reported | [0.0 d](/filings/0001493152-25-009872.md) | [17.3](/filings/0001493152-26-023091.md) | [0.1 d](/filings/0001493152-26-037377.md) | [(17.4) d](/filings/0001493152-25-023656.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.4](/filings/0001493152-23-040633.md) | [7.1](/filings/0001493152-24-019330.md) | [7.1](/filings/0001493152-24-031275.md) | [7.3](/filings/0001493152-24-045795.md) | [7.7](/filings/0001641172-25-011020.md) | [7.7](/filings/0001493152-25-011978.md) | [7.7](/filings/0001493152-25-023656.md) | [9.4](/filings/0001641172-25-011020.md) | [9.6](/filings/0001493152-25-011978.md) | [13.7](/filings/0001493152-25-023656.md) | [30.4](/filings/0001493152-26-023091.md) | [39.2](/filings/0001493152-26-037377.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 40,143,626 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001493152-26-037377.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.